<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00078390</url>
  </required_header>
  <id_info>
    <org_study_id>0207P1421</org_study_id>
    <nct_id>NCT00078390</nct_id>
  </id_info>
  <brief_title>Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I/II Study of the Safety, Pharmacokinetic Interaction and Efficacy of S-3304 in Combination With Standard Therapy in Patients With Locally Advanced Non-small Cell Lung Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <brief_summary>
    <textblock>
      A study to measure the safety and effectiveness of S-3304 when given in combination with
      conventional chemo-radiation therapy in patients with locally advanced non-small cell lung
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A two part study to evaluate the safety and efficacy of S-3304 in combination with standard
      therapy in patients with locally advanced non-small cell lung cancer. The first part of the
      study is a Phase I design to evaluate the maximum tolerated dose of S-3304 when given in
      combination with radiation and paclitaxel/carboplatin chemotherapy that is appropriate for
      further evaluation. The second part of the study is a randomized Phase II design to evaluate
      the efficacy of recommended S-3304 dose in combination with chemo-radiation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2003</start_date>
  <completion_date type="Actual">October 26, 2006</completion_date>
  <primary_completion_date type="Actual">September 28, 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The Phase 1 part of the study will determine the tolerable dose of S-3304 in the presence of radiation and paclitaxel/carboplatin chemotherapy in a non-randomized manner.
The Phase 2 part will compare the effect combination of S-3304 in addition to chemo-irradiation therapy to the effect of radiation and paclitaxel/carboplatin chemotherapy alone on small cell lung tumors</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Stage IIIA Non Small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>S-3304 plus chemo-irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The tolerable dose of S-3304 determined in the Phase 1 part of the study will be dosed BID along with a standard of care regimen of radiation and paclitaxel/carboplatin chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemo-irradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The standard of care regimen of radiation and paclitaxel/carboplatin chemotherapy will be administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-3304</intervention_name>
    <description>S-3304 will be administered at the tolerable dose BID along with chemo-irradiation</description>
    <arm_group_label>S-3304 plus chemo-irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chemo-irradiation</intervention_name>
    <description>Standard of care chemo-irradiation</description>
    <arm_group_label>S-3304 plus chemo-irradiation</arm_group_label>
    <arm_group_label>Chemo-irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  newly diagnosed non-small cell lung cancer of stage IIIA non-resectable or of stage
             IIIB without pleural effusion

          -  ECOG performance status 0-1

          -  adequate organ function

          -  clinically indicated and able to receive conventional chemoradiation therapy

        EXCLUSION CRITERIA

          -  patients with prior history of cancer, other than basal cell carcinoma after
             appropriate treatment, or prior systemic chemotherapy treatment

          -  patients with other serious intercurrent illness including HIV/AIDS, or
             contraindicated for paclitaxel/carboplatin or thoracic irradiation treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Scripps Cancer Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lombardi Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center-East Orange (study available to veterans only)</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>07108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2004</study_first_submitted>
  <study_first_submitted_qc>February 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2004</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>Lung carcinoma</keyword>
  <keyword>Non small cell lung cancer</keyword>
  <keyword>Stage IIIA non small cell lung cancer</keyword>
  <keyword>Stage IIIB non small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Stage III</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>radiation</keyword>
  <keyword>chemoradiation</keyword>
  <keyword>matrix metalloproteinases</keyword>
  <keyword>neovascularization</keyword>
  <keyword>antiangiogenesis</keyword>
  <keyword>type IV collagenases</keyword>
  <keyword>Unresectable locally advanced non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>S 3304</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

